ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies
Executive Summary
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
You may also be interested in...
Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.
Medicare Price Negotiation Targeting Only Post-Exclusivity Drugs Proposed By Moderate House Democrats
Legislation authorizing the US government to directly negotiate drug prices with manufacturers failed to pass in one key House committee as a trio of Democrats joined Republicans to vote against advancing the policy.